Review and Evaluation of Pharmacology and Toxicology Data Division of Analgesics, Anti-inflammatory, and Ophthalmic Drug Products

HFD-550

Reviewer: Susan D. Wilson, D.V.M., Ph.D.

Electronic File Number:

NDA Number:

21-042

Serial Number:

Submission Date:

November 23, 1998

Type of Submission:

Original NDA

Information to Sponsor:

Yes (X)

Completion Date:

May 7, 1999

Sponsor or Agent:

Merck & Co., Inc.

Sumneytown Pike P.O. Box 4, BLA-20 West Point, PA 19486

Manufacturer (if different) for drug substance:

Drug name:

1° - VioxxTM

2° - Rofecoxib

3° - MK-996, MK-0966, L-748,731

Chemical Name: 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone

CAS Number (if provided by sponsor):

Structure: C17H14O4S

Molecular Weight: 314.36

Relevant IND/NDA/DMF

NDA 21-052

INDEX OF STUDIES

1.	PHARM	ACOLOGY	9-19
	1.1 Pharm	nacological Studies of L-748,731 - In Vitro Studies	9
		In Vitro Studies of L-748,731	9
		Miscellaneous Specificity Studies	10
	1.1.3	Identification of COX-1 [PGHS] in Gastrointestinal Tract	11
		Receptor Binding Specificity	11
	1.1.5	Additional In Vitro Biochemical Studies of MK-0966	12
	1.2 Pharm	nacological Studies of L-748,731 - In Vivo Studies	13
		Effect of L-748,731 on Carrageenan-Induced Rat Paw Edema	13
	1.2.2	Effect of L-748,731 on LPS Induced Pyrexia in Conscious Rats	13
	1.2.3	Effect of L-748,731 on LPS Induced Pyrexia in Conscious Squirrel Monkeys	14
	1.2.4 1.2.5	Effect of L-748,731 on Acute Inflammatory Hyperalgesia Induced by Carageenan Effect of L-748,731 on Chronic Inflammatory Hyperalgesia Induced by Injection	14
		of Freund's Complete Adjuvant into the Ankle Joint	14
	1.2.6	Effects of L-748,731 on Adjuvant Induced Arthritis in Lewis Rats	15
	1.2.7	Effects of L-748,731 on Fecal ⁵¹ Cr Excretion in Rats	15
		Effects of L-748,731 on Fecal ⁵¹ Cr Excretion in Squirrel Monkeys	15
		Effect of MK-0966 on Urinary 51 Cr Excretion in Rats	16
		Effects of L-748,731 on Rat Urinary PGE2 Excretion	16
	1.2.11	Effects of L-748,731 on Urinary PGE2 Excretion in Anesthetized Dogs on	
		AA-induced PGE2 Formation in LPS Stimulated Dog Whole Blood Ex Vivo	17
	1.2.12	Effects of L-784,731 on Urinary Eicosanoid and Sodium Excretion in Conscious	
		Male Dogs	17
	1.3 Sumn	nary of Pharmacology	17
2.	SAFETY	PHARMACOLOGY	19-20
	2.1 In Viv	Ø Studies	19
	2.1.1	Ancillary Pharmacology of L-748,731-000R, A Selective Cyclooxygenase II [COX-2] Inhibitor	
	212	Effect of the Selective Cyclooxygenase II Inhibitor [COX-2], L-748,731, on	19
	2.1.2		
		Renal Function and Electrolyte Excretion in Conscious, Volume-Depleted, Normotensive Rats	20
		가는 사람들이 되었다. 그는 사람들은 사람들이 되었다면 보고 하는 것이 되었다. 그는 사람들이 되었다면 되었다. 	20
	2.2 Summ	nary of Safety Pharmacology	20
3.		ACOKINETICS/TOXICOKINETICS	21-64
		nacokinetic Studies - Absorption, Distribution, Metabolism, Excretion Studies	21
	3.1.1	Absorption, Distribution, Metabolism, and Excretion of L-748,731 in Rats	
		and Dogs	21
		L-748,731: Dose-Dependence of MK-0966 Pharmacokinetics in Rats and Dogs	23
	3.1.3		24
	3.1.4	Study of the Potential for Covalent Binding between L-748,731 and Proteins	24
		nacokinetic Studies – Absorption	24
	3.2.1	The Effect of Food on the Absorption Kinetics of MK-0966 in Dogs Following	
		Oral Administrations	24

3.3	Pharmacokinetic Studies - Distribution				
	3.3.1 T	Fissue Distribution of Radioactivity Following a Single Intravenous Dose of ¹⁴ C]L-748,731 in Male Rats	25		
	3.3.2 I	Distribution of MK-0966 and Its Metabolite, L-755,190, in the Gastrointestinal Tract of the Rat One Hour After Oral Doses of [14C]MK-0966 or [14C]L-755,190			
	3.3.3 I	Distribution of MK-0966 and Its Metabolite, L-755,190, in the Gastrointestinal Fract of the Rat 1, 4, and 6 Hours After Oral Doses of [14C]MK-0966 or	26		
		¹⁴ C]L-755,190	26		
	3.3.4 C	INS Penetration of MK-966 [L-748,731] in the Rat	26		
3.4		cokinetic Studies – Excretion	27		
	3.4.1 B	Biliary Excretion of MK-0966 in Rats Following Administration of [14C]MK-0966 t 2 mg/kg I.V. or 5 mg/kg P.O. and Identification of Two Biliary Metabolites	27		
	3.4.2 T	The Effect of Bile Flow on the Recirculation of MK-0966 and L-755,190 in Rats following Intravenous [2 mg/kg] and Oral [5 mg/kg] Administration of			
		*C]MK-0966	27		
	3.4.3 B	Biliary Excretion in Dogs Following Administration of [14C]L-748,731 at 2 mg/kg.V. or 5 mg/kg P.O.	28		
3.5	Pharmac	okinetic Studies – Metabolism	29		
		n Vitro Studies	29		
	3.5.1.i	. Microsomal Studies	29		
	a. S	tudy of the Oxidative [Phase I] Biotransformations	29		
	b. Id	dentification of L-755,190 as the Major Metabolites of MK-0966 in Incubations	-		
	w	with Liver Microsomal Preparations From Phenobarbital-Pretreated Rats	29		
	c. T	he Cytochrome P-450 Mediated Oxidation of MK-0966 to L-755,190 by Human	-		
	L	iver Microsomes	29		
	d. S	tudy of L-748,731 on Human Cytochrome P450 3A4 Metabolizing Enzyme	30		
	e. S	tudy of Phase II Hepatic Microsome Metabolism of the Hydroxylated Metabolite f L-748,731 – Conjugation of Glucuronic Acid	30		
		i Cytosol Studies	30		
		eductive Metabolism of MK-0966 by Human Liver Cytosol	30		
		ii Subcellular Fraction Studies	30		
		he Metabolism of MK-0966 by Liver Subcellular Fractions From Human, Monke	 V		
	D	og and Rat	y, 30		
		on-Cytochrome P-450-Mediated Oxidation of MK-0966 to L-755,190 by Hepatic	50		
	S	ubcellular Fractions	31		
		inetics of the In Vitro Metabolism of MK-0966 by Human Liver S9 and Cytosolic			
		ractions	31		
	3.5.1.iv	v.Hepatocyte Preparation Studies	32		
		tudy of the Biotransformation of L-748,731 by Rat Hepatocytes	32		
	b. E	ffects of L-748,731 on Cytochrome P450 3A Protein Levels in Rat Hepatocytes	32		
	3.5.2 In	i Vivo Studies	32		
	3.5.2.i	Mechanistic Studies on the Metabolism of MK-0966 in the Rat. Investigations with Oxygen-18-Labeled Probes	32		
	3.5.2.ii	그는 그들은 학생들 때문에 한 등에 가는 그는 그는 사람들은 그는 그들은 그는 그들은 그들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람			
an		ii Exploratory Enzyme Induction Study in Mice of L-748,731, a COX-2			
	7.5	Inhibitor	33		
		Exploratory Enzyme Induction Study in Rats of L-748,731, a COX-2 Inhibitor Western and Northern Blots from Exploratory Enzyme Induction Study in	34		
		Mice of L-748,731	35		

	3.5.2	vi Western and Northern Blots from Exploratory Enzyme Induction Study in Rats	
	250	of L-748,731	35
	3.5.2	vii In Situ Metabolism of [14C]L-755,190, a Metabolite of MK-0966 in the Rat	
	257	Isolated Intestinal Segment	36
	3.3.2	viii Isolation and Identification of L-755,190 and Its Glucuronide Conjugate in the	
	252	Urine of Rats Dosed Intravenously with [14C]MK-0966 at 2 mg/kg	36
	3.3.2	ix Metabolite Profiles of Urine From Mice and Rats Following Oral	
	252	Administration of [14C]MK-0966 at 100 mg/kg	37
	3.5.2		
	252	MK-0966 in Urine of Rats Dosed Orally with MK-0966 [100 mg/kg]	37
	3.3.2	xi Metabolite Profiles of Plasma and Urine From Mice Following Oral	
		Administration of [14C]MK-0966 at 5 mg/kg and of Plasma from Rats After	
	252	Intravenous [2 mg/kg] or Oral [5 mg/kg] Administration of [14C]MK-0966	37
	3.3.2	xi Isolation and Identification of trans-Dihydro MK-0966 Lactone, a Metabolite	
		of MK-0966, From Urine of Dogs Following Intravenous Administration of	
		[¹⁴ C]MK-0966	38
3.6	Pharm	acokinetic Studies - Studies to Assess Potential Drug-Drug Interaction	38
	3.6.1	An In Vitro Plasma Protein Binding Displacement Interaction Study with	
		[14C]MK-0966 and [14C]Salicylic Acid	38
	3.6.2		٥٠
		by Human Liver Microsomes, S9 Fractions and Cytosol	39
	3.6.3	Evaluation of MK-0966 as an Inhibitor of Human Liver Microsomal Cytochrome	יכנ
		P-450 Activity	39
	3.6.4	Characterization of P-450 Activities in Microsomal Samples Using Testosterone	
		Hydroxylation Assay	39
3.7		okinetic Studies – Acute Studies in Mice	40
	3.7.1	Single Dose Oral Toxicity Study in Mice	40
3.8	Toxico	kinetic Studies – Acute Studies in Rats	41
	3.8.1	Single Dose Oral Toxicokinetic Study in Rats	41
	3.8.2		41
3.9	Toxico	kinetic Studies - Repeat Dose Studies in Mice	43
	3.9.1	Five-Week Oral Toxicokinetic Study in Mice	43
	3.9.2	L-748,731: Twenty-Seven-Week Oral Toxicokinetic Study in Mice	44
	3.9.3	L-748,731: Twenty-Seven-Week Oral Toxicokinetic Study in Mice	46
3 1	0 Toxic	okinetic Studies – Multiple Dose Rat Studies	
J.1		L-748,731: Sixteen Day Oral Toxicokinetic Study in Male Rats	47
	3.10.1	L-748,731: Sixteen Day Oral Toxicokinetic Study in Male Rats L-748,731: Sixteen Day Oral Toxicokinetic Study in Female Rats	47
	3.10.2	L-748,731: Twenty-Seven-Week Oral Toxicokinetic Study in Rats	49
	3.10.3	L-746,731. Twenty-Seven-week Oral Toxicokinetic Study in Rats	52
3.1	1 Toxic	okinetic Studies – Multiple Dose Dog Studies	53
		MK-0966: Sixteen-Day Oral Toxicokinetic Study in Dogs	53
, 1	3 T- '		
ا.د	2 10X1C	okinetic Studies – Reproduction Toxicokinetics in Rats	54
		L-748,731: Oral Toxicokinetic Study in Pregnant and Nonpregnant Rats	54
	3.12.2	L-748,731: Oral Toxicokinetic Study in Lactating Rats	57

	3.13 Toxicokinetic Studies – Reproduction Toxicokinetics in Rabbits 3.13.1 L-748,731: Oral Toxicokinetic Study in Pregnant and Nonpregnant Rabbits	58 58
	3.14 Pharmacokinetics of L-755,190, The 5-Hydroxy Furanone Metabolite of L-748,731 3.14.1 Absorption, Distribution, Metabolism and Excretion of L-755,190 in Rats	60
	and Dogs 3.14.2 Biliary Excretion of L-755,190 in Rats Following Administration of	60
	['*C]L-755,190 at 2 mg/kg I.V. and 5 mg/kg P.O. 3.14.3 The Effect of Bile Flow on Recirculation of MK-0966 and L-755,190 in Rats	61
	Following Intravenous [2 mg/kg] and Oral [5 mg/kg] Administration of [14C]L-755,190	61
	3.15 Summary of Pharmacokinetics and Toxicokinetics	62
4.	TOXICOLOGY	65-97
	4.1 Single Dose Studies	65
	4.2 Repeat Dose Studies – Dogs	65
	4.2.1 Exploratory 15-Day Oral Toxicity Study in Dogs	65
	4.2.2 Fourteen-Week Oral Toxicity Study in Dogs	66
	4.2.3 L-748,731: Fifty-Three-Week Oral Toxicity Study in Dogs with a 27-Week	
	Interim Necropsy: Final Report 4.2.4 Sixteen-Day Intravenous Toxicity Study in Dogs with L-748,731	69 71
	4.3 Repeat Dose Studies - Rats	72
	4.3.1 Exploratory 15-Day Oral Toxicity Study in Rats	72
	4.3.2 L-752,860 and L-748,731: Exploratory Sixteen-Day Oral Toxicity Study in Rats	74
	4.3.3 L-748,731, Ibuprofen: Exploratory Fifteen-Day Cyclooxygenase Inhibition Study In Female Rats	75 75
	4.3.4 Fourteen-Week Oral Range-Finding Study in Rats	77
	4.3.5 Fourteen Week Oral Toxicity Study in Rats	80
	4.3.6 L-748,731: Fourteen-Week Oral Toxicity Study in Rats with a Seven-Week	
	Interim Necropsy and a Recovery Period	82
	4.3.7 Twenty-Seven Week Oral Toxicity Study in Rats	84
	4.3.8 L-748,731: Fifty-Three-Week Oral Toxicity Study in Rats with a 27-Week Interim Necropsy: Final Report	
		88
	4.3.9 L-748,731: Fifty-Three-Week Oral Gastrointestinal Toxicity Study in Rats 4.3.10 Fifteen-Day IV Toxicity Study in Rats	90 91
		91
	4.4 Repeat Dose Studies – Mice	93-95
	4.4.1 Fourteen-Week Oral Range-Finding Study in Mice	93
	4.5 Summary of Toxicology	95-97
5.	GENOTOXICITY	98-108
	5.1 In Vitro Assays	98
	5.1.1 Mutagencity Assays	98
	5.1.1.i Microbial Mutagenesis Assay	98
	5.1.1.ii L-748,731: V-79 Mammalian Cell Mutagenesis Assay	99
	5.1.2. Clastogencity Assay 5.1.2.i Chromosomal Aberrations In Vitro in Chinese Hamster Ovany Cells	100
	5.1.2 i Chromosomal Aberrations In Vitro in Chinese Hamster Oversy Calls	100

	5.1.2.ii L-748,731: Assay for Chromosomal Aberrations <i>In Vitro</i> in Chinese Hamster Ovary Cells	101
	5.1.2.iii <i>In Vitro</i> Alkaline Elution/Rat Hepatocyte Assay	101
	5.2 In Vivo Assays	104
	5.2.1 In Vivo Alkaline Elution/Rat Liver DNA Damage Assay in Male Rats	104
	5.2.2 In Vivo Alkaline Elution/Rat Liver DNA Damage Assay in Female Rats	106
	5.2.3 MK-0966: Assay for Chromosomal Aberrations In Vivo, in Mouse Bone Marrow	106
	5.3 Summary of Genotoxicity	108
6.	CARCINOGENCITY	109-130
	6.1 Carcinogenicity – Rat Study	109
	6.1.1 L-748,731: One Hundred-Six-Week Oral Carcinogenicity Study in Rats	109
	6.2 Carcinogenicity – Mice Study	116
	6.2.1 L-748,731: One Hundred-Six-Week Oral Carcinogenicity Study in Mice	116
	6.2.2 L-748,731: One Hundred-Four-Week Oral Carcinogenicity Study in Mice	124
	6.3 Summary of Carcinogenicity	129
7.	REPRODUCTIVE TOXICOLOGY	131-165
	7.1 Fertility Studies - Including Assessment of Ovulation and Cyclicity	131
	7.1.1 Oral Fertility Study in Female Rats	131
	7.1.2 L-748,731: Oral Fertility Study in Female Rats with a Recovery Period	132
	7.1.3 L-748,731: Oral Ovulation/Fertilization Study in Female Rats	135
	7.1.4 L-748,731: Oral Estrous/Cyclicity/Ovulation/Fertilization Study in Female Rats 7.1.5 L-748,731: Oral Fertility Study in Female Rats with Gestation Days 15 and 21	137
	Laparotomies	138
	7.1.6 L-748,731: Oral Fertility Study in Male Rats	140
	7.2 Implantation Study	142
	7.2.1 L-748,731: Oral Implantation Study in Rats	142
	7.3 Developmental Studies	143
	7.3.1 Developmental Studies – Rabbit	143
	7.3.1.i Oral Range-Finding Study in Non-Pregnant Rabbits	143
	7.3.1.ii Oral Range-Finding Study in Pregnant Rabbits	144
	7.3.1.iii Oral Developmental Toxicity Study in Rabbits	146
	7.3.2 Developmental Studies – Rat	148
	7.3.2.i Oral Range-Finding Reproduction Study in Female Rats	148
	7.3.2.ii Oral Developmental Toxicity Study in Rats	149
	7.4 Gestation/Lactation Study	152
	7.4.1 L-748,731: Fostering/Cross-Fostering Study in Rats	152
	7.5 Late Gestation- Including Lactation Period and Postweaning Development	154
	7.5.1 L-748,731: Oral Length of Gestation and Parturition Study in Female Rats	154
	7.5.2 L-748,731: Oral Range-Finding Late Gestation and Lactation Study in Rats	156

	7.5.3	L-748,731: Oral Late Gestation and Lactation Study in Rats with Postweaning Evaluation	
	7.5.4	MK-0966: Oral Study in Rats to Assess Effects on Fetal Ductus Arteriosus	158
		or of the stady in Rais to Assess Effects on Fetal Ductus Arteriosus	162
	7.6 Sumr	nary of Reproduction Toxicology	163
8.	SPECIA	L TOXICOLOGY	
		tion Studies	166-175
	8.1.1	L-748,731: Exploratory Dermal Irritation Study in Rabbits	166
	8.1.2	Effect of L-748,731 in the Bovine Corneal Opacity and Permeability [BCOP] Assay	166
	813		166
		L-748,731: Exploratory Primary Eye Irritation Study in Rabbits	167
	8.2 Photo	toxicity Study	168
	8.2.1	Acute Oral Phototoxicity Study in Mice	168
	8.3 Speci	al Studies Conducted With The Metabolite	
	8.3.1	L-748,706; L-755,190; Ibuprofen: Exploratory Fifteen-Day Cyclooxygenase	169
		Inhibition Study in Female Rats	1.00
	8.3.2	Five-Week Oral Toxicity Study in Rats	169
	8.3.3	Fifteen-Day Intravenous Toxicity Study in Rats with 1,755, 100	170
	8.3.4	Sixteen-Day Intravenous Toxicity Study in Dogs	172
		사는 하는 사람들은 가는 없는 것 하는 것들은 사람들이 가장하게 하는 것이 없는 사람들이 가장 하는 것이 없는 것이다.	173
	8.4 Summ	ary of Special Toxicology	174
9	OVERAL	L SUMMARY	175-182
		- 대한 사람들이 보고 있는데 하는데 보고 되었다. 그리고 있는데 하는데 하는데 하는데 되었다. 그리고 있는데 하는데 하는데 하는데 하는데 하는데 하는데 하는데 하는데 하는데 하	1/3-182
10	RECOM	MENDATIONS	182-183
11	LABELIN	G REVIEW	183 186

BEST POSSIBLE COPY

APPEARS THIS WAY ON ORIGINAL

Drug Class: COX-2 Inhibitor

Indication: "Acute and chronic treatment of the signs and symptoms of osteoarthritis, relief of acute pain, and treatment of primary dysmenorrhea"

Clinical Formulation (and components): Tablet form in two strengths: 12.5 and 25 mg.

MK-0966 Microcrystalline Cellulose Lactos e Hydroxypropyl Cellulose Croscam ellose Sodium Yellow Ferric Oxide Magnesium S bescabe Total		125 mg dose 25 mg dose
Lactose Hydroxygropyl Schinosp Ciroscam ellose Sodium Yellow Ferric Oxide Magnesium Shearabe	VIX-0966	12.50 25.00
Laciose Hydroxypropyl Selinios Croscam ellose Sodium Yellow Ferric Oxide Magnesium Stearabe	Market Market Control	
Croscam ellose Sodium Yellow Ferric Oxide Wagnesium Stearate	Annual Control of the Control of	
Yellow Ferric Oxide Vlagnesium S bescabe		
And the second s	/	
CODI	ASCLUEZIMW & peacate	
in the control of the	'obl	general control of the common the design and the control of the co

Route of Administration: oral

<u>Proposed Clinical Protocol</u>: The maximum recommended dose for osteoarthritis is 25 mg daily. The maximum recommended dose for acute pain and dysmenorrhea is 50 mg daily for ≤5 days.

Studies Reviewed within this submission:

Report No.	Report Date	Study Title	Test Material Lot
		PHARMACOLOGY STUDIES	
	Nov. 1, 1994	F-21: Pharmacological studies of L-748,731 [Vol. 1.42; p. F-227]	
	Oct. 22, 1997	F-22: Additional In Vitro Biochemical Studies of MK-0966 [Vol. 1.42; p. F-356]	
	Oct. 22, 1997	F-23: Additional Pharmacological Studies of MK-0966 [Vol. 1.42; p. F-374]	
	Nov. 1, 1994	F-26: Effects of L-748,731 on Adjuvant-Induced Arthritis in Lewis Rats [Vol. 1.43; F-480]	
Asia Natantan	SA	FETY PHARMACOLOGY STUDIES	
	Oct. 31, 1994	F-24: Ancillary Pharmacology of L-748,731-000R, a Selective Cyclooxygenase II [COX-2] Inhibitor[Vol. 1.43; F-398]	
	Oct. 31, 1994	F-25: Effect of the Selective Cyclooxygenase II Inhibitors [COX-2], L-748,731-000R on Renal Function and Electrolyte Excretion in Conscious, Trained Dogs and Conscious Volume Depleted, Normotensive Rats [Vol. 1.43; F-424]	
		TOXICOLOGY STUDIES	
Maria de la casa de la	Rain and	Single Dose Studies	<u> Tarihi waka kata kata kata kata kata kata kata</u>
TT #94-2639 TT #94-2640 TT #94-2641 TT #94-2642	July 29, 1994	A-1: L-748,731: Acute Oral and Intraperitoneal Toxicity Studies in Mice and Rats [Vol. 1.7; p. A-21]	L-748,731-000R009

Report No.	Report Date	Study Title	Test Material Lot
		Repeat Dose Studies	
Dog studies			
TT #94-020-0	May 6, 1994	B-1: L 748,731: Exploratory Fifteen-Day Oral Toxicity Study in Dogs [Vol. 1.8; B-125]	L-748,731-000R004
TT #94-040-0	Aug. 3, 1995	B-2: L-748,731: Fourteen-Week Oral Toxicity Study in Dogs [Vol. 1.9; B-183 and Vol. 1.10; B-339]	L-748,731-000R009
TT #95-003-0	June 19, 1996	B-3: L-748,731: Fifty-Three-Week Oral Toxicity Study in Dogs with a 27-Week Interim Necropsy: Final Report [Vol. 1.10; B-474 and Vol. 1.11; B-782]	L-748,731-000R014
TT #95-077-0	Apr. 25, 1996	B-18: L-748,731: Sixteen-Day Intravenous Toxicity Study in Dogs [Vol. 1.20; p. B-4232]	L-748,731-000R014
Rat studies			
TT #93-149-0	Mar 2, 1994	B-4: L 748,731: Exploratory Fifteen-Day Oral Toxicity Study in Rats [Vol. 1.11; B-910]	L-748,731-000R003
TT #94-615-0	Aug. 31, 1995	B-5: L-748,731: Fourteen-Week Oral Toxicity Study in Rats [Vol. 1.11; B-100 and Vol. 1.12; B-1184]	L-748,731-000R009
TT #95-614-0	May 2, 1996	B-6: L-748,731: Fourteen-Week Oral Toxicity Study in Rats with a Seven-Week Interim Necropsy and a Recovery Period [Vol. 1.13; B-1512]	L-748,731-000R014
TT #95-601-0	Sept. 26, 1995	B-7: L-748,731: Twenty-Seven-Week Oral Toxicity Study in Rats [Vol. 1.13; B-1651, Vol. 1.14; B-1918; and Vol. 1.15; B-2259]	L-748,731-000R014
TT #95-018-0	Sept. 24, 1995	B-8: L-748,731: Fourteen-Week Oral Range-Finding Study in Rats [Vol. 1.15; B-2400 and Vol. 1.16; B-2612]	L-748,731-000R014 L-748,731-000R015
TT #95-055-0	Jan. 18, 1996	B-11: L748,731, Ibuprofen: Exploratory fifteen-Day Cyclooxygenase Inhibition Study in Female Rats [Vol. 1.17; p. B-3018]	L-748,731-000R009
TT #95-615-0	Sept. 28, 1995	B-13: L-752,860 and L-748,731: Exploratory Sixteen-Day Oral Toxicity Study in Rats [Vol. 1.17; p. B-3102]	L-748,731-000R014 L-752.860-000R005
TT #95-045-0	Nov. 25, 1996	B-14: L-748,731: Fifty-Three-Week Oral Toxicity Study in Rats with a 27-Week Interim Necropsy: Final Report [Vol. 1.17; B-3209; Vol. 1.18 B-3420, Vol. 1.19; p, B-3765]	L-748,731-000R014
TT #96-090-0	Mar. 16, 1996	B-15: L-748,731: Fifty-Three-Week Oral Gastrointestinal Toxicity Study in Rats [Vol. 1.19; p, B-3870]	L-748,731-000R014
TT #95-075-0,-1	Apr. 29, 1996	B-19: L-748,731: Fifteen-Day Intravenous Toxicity Study in Dogs [Vol. 1.20; p. B-4477 and Vol. 1.21; p. B-4577]	L-748,731-000R014
Mouse Study	A		
TT #95-610-0	Oct. 27, 1995	B-16: L-748,731: Fourteen-Week Oral Range-Finding Study in Mice [Vol. 1.19; p. B-3987]	L-748,731-000R014
ing e e e e e e e e e e e e e e e e e e e		CARGINOGENICITY STUDIES	salasa salasa ili
Rat Study			
TT #95-076-0	Jul. 27, 1998	E-1: One-Hundred-Six-Week Oral Carcinogenicity Study in Rats [Vol. 1.35: p. E-37 and Vol. 1.36; p. E-399]	L-748,731-000R015 and 1 748,731-000R027
Mouse Studies	<u> </u>		
TT #96-603-0, -1	Jul. 23, 1998	E-3: One-Hundred-Six-Week Oral Carcinogenicity Study in Mice [Vol. 1.37: p. E-705 and Vol. 1.38; p. E-1132]	748,731-000R027
TT #96-605-0, -1	Jul. 23, 1998	E-5: One-Hundred-Four-Week Oral Carcinogenicity Study in Mice [Vol. 1.37: p. E-1464 and Vol. 1.38; p. E-1132]	748,731-000R032
		TOXICOKINETIC STUDIES	
		Single Dose Studies	
Mouse Study	A STATE OF THE STA		18.8
TT#95-617-0	Oct. 16, 1995	A-2: L-748,731: Single Dose Oral Toxicokinetic Study in Mice [Vol. 1.7; p. A-34]	L-748,731-000R14

Report No.	Report Date	Study Title	Test Material Lo
Rat Studies			1
TT #95-027-0	Sept. 14, 1995	A-3: L-748,731: Single Dose Oral Toxicokinetic Study in Rats [Vol. 1.7; p. A-79]	L-748,731-000R009
TT #96-025-0	Nov. 26, 1997	A:-4 L-748,731: Single Dose Oral Toxicokinetic Study in Rats [Vol. 1.7; p. A-132]	L-748,731-000R027
		Repeat Dose Studies	
Mouse studies	4450 and a 1		Leave tell, and the second of
TT #95-611-0	Oct 27, 1995	B-17: L-748,731: Five-Week Oral Toxicokinetic Study in Mice [Vol. 1.20; p.B-4170]	L-748,731-000R014
TT #96-604-0	Jan. 9, 1997	E-4: L-748,731: Twenty-Seven-Week Oral Toxicokinetic Study in Mice [Vol. 1.38; p. E-1381]	L-748,731-000R027
TT #96-606-0	Jan. 9, 1997	E-6: L-748,731: Twenty-Seven-Week Oral Toxicokinetic Study in Mice [Vol. 1.38; p. E-1381]	L-748,731-000R032
Rat studies	Berthing was a control		
TT #95-022-0	Oct. 30, 1995	B-9: L-748,731: Sixteen-Day Oral Toxicokinetic Study in Male Rats [Vol. 1.16; p. B-2863]	L-748,731-000R015
TT #95-076-1	Nov. 12, 1996	E-2: L-748,731: Twenty-Seven-Week Oral Toxicokinetic Study in Rats [Vol. 1.36; p. E-613]	
TT # 95-022-1	Nov. 30, 1995	B-10: L-748,731: Sixteen-Day Oral Toxicokinetic Study in Female Rats [Vol. 1.16; p. B-2940]	L-748,731-000R015
TT #95-709-0 TT #95-709-1 TT #95-709-2	Oct. 13 1995	C-18: L748,731: Oral Toxicokinetic Study in Pregnant and Nonpregnant Rats [Vol. 1.29; p. C-2627]	L-748,731-000R009
TT #96-712-0	Oct. 14, 1996	C-19: L-748,731: Oral Toxicokinetic Study in Lactating Rats [Vol. 1.30; p. C-2738]	L-748,731-000R027
Rabbit studies			
TT #95-722-1,-1	Dec. 28, 1995	C-4: L-748,731: Oral Toxicokinetic Study in Pregnant and Nonpregnant Rabbits [Vol. 1.23; p. C-337]	L-748,731-000R009
		PHARMACOKINETIC STUDIES	
TT #93-281-0,-2 Gene-Tox TT #93- 8980	Memo Dec. 9, 1993	B-24: Exploratory Enzyme Induction Study in Rats of L-748,731, a COX-2 Inhibitor submitted by D. Patrick [Vol. 1.21; B-4935]	Not provided
		G-1: Absorption, Distribution, Metabolism, and Excretion of L-748,731 in Rats and Dogs [Vol. 1.45; p. G-60]	
	April 2, 1996	G-2: Dose-Dependence of MK-0966 Pharmacokinetics in Rats and Dogs [Vol. 1.45; p. G-152]	
	April 1, 1996	G-3: Absorption, Distribution, Metabolism and Excretion of L-755,190 in Rats and Dogs [Vol. 1.45; G-190]	[¹⁴ C]L-755,190-001K001
	March 2, 1998	G-4: Mechanistic Studies on the Metabolism of MK-0966 in the Rat. Investigations with Oxygen-18-Labeled Probes [Vol. 1.45; G-237]	[¹⁸ O ₂]L-748,731-003X001 [¹⁸ O ₁]L-755,190-002M001
	Nov. 1, 1997	G-6: Biliary Excretion of MK-0966 in Rats Following Administration of [\(^{14}C)MK-0966\) at 2 mg/kg/ I.V. or 5 mg/kg/P.O. and Identification of Two Biliary Metabolites [Vol. 1.45; p. G-330]	[¹⁴ C]L-748,731-002V001
	Jan. 29, 1998	G-7: Biliary Excretion of L-755,190 in Rats Following Administration of [\(^1\C)\L-755,190\) at 2m/kg I.V. or 5 mg/kg P.O. [Vol. 1.45; p. G-348]	[1*C]L-755,190-001K002 and 3
	Nov. 11, 1997	G-8: Biliary Excretion in Dogs Following Administration of [14C]L-748,731 at 2m/kg I.V. or 5 mg/kg P.O. [Vol. 1.45; p. G-362]	[14C]L-748,731-002V001, 002, and 008
	Oct. 26, 1997	G-9: The Effect of Food on the Absorption Kinetics of MK-0966 in Dogs Following Oral Administration [Vol. 1.45; p. G-377]	L-748,731-000R009
	March 12, 1998	G-10: The Effect of Bile Flow on the Recirculation of MK-0966 and L-755,190 in Rats Following Intravenous [2mg/kg] and oral [5 mg/kg] Administration of [14C]MK-0966 [Vol. 1.45; p. G-388]	[¹⁴ C]L-748,731-002V008

Report No.	Report Date	Study Title	Test Material Lo
	Dec. 16, 1997	G-11: The Effect of Bile Flow on the Recirculation of MK-0966 and L-755,190 in Rats Following Intravenous [2mg/kg] and oral [5 mg/kg] Administration of [14C]L-755,190 [Vol. 1.45; p. G-388]	[¹⁴ C]L-755,190-001K001, 002, and 003
	July 14, 1995	G-12: Tissue Distribution of Radioactivity Following a Single Intravenous Dose of [14C]L-748,731 in Male Rats [Vol. 1.46; p. G-462	Not provided
	Oct. 15, 1997	G-14: Distribution of MK-0966 and Its Metabolite L-755,190 in the Gastrointestinal Tract of the Rat One Hour After Oral Doses of [14C]MK-0966 or [14C]L-755,190 [Vol. 1.46; p. G-570]	[¹⁴ C]L-748,731-002V002 [¹⁴ C]L-755,190-001K001
	Oct. 19, 1997	G-15: Distribution of MK-0966 and Its Metabolite L- 55,190 in the Gastrointestinal Tract of the Rat 1, 4, and 6 Hours After Oral Doses of [14C]MK-0966 or [14C]L- 755,190 at 5 mg/kg [Vol. 1.46; p. G-582]	[¹⁴ C]L-748,731-002V007 -[¹⁴ C]L-755,190-001K002
	Dec. 15, 1997	G-17: An In Vitro Plasma Protein Binding Displacement Interaction Study With [14C]MK-0966 and [14C]Salicylic Acid [Vol. 1.46; G-604]	[¹⁴C]L-748,731-002∨008
	Nov. 5, 1997	G-20: Isolation and Identification of L-755,190 and Its Glucuronide Conjugate in the Urine of Rats Dosed Intravenously with [14C]MK-0966 at 2 mg/kg [Vol. 1.46; G-622]	[¹⁴ C]L-748,731-002V002
	Dec. 2, 1997	G-21: Metabolite Profiles of Urine From Mice and Rats Following Oral Administration of [14C]MK-0966 at 100 mg/kg [Vol. 1.46; p. G-638]	['*C]L-748,731-002V007
	Dec. 6, 1997	G-22: Identification of the 3',4'-Dihydrodiol and 4'-Phenol Sulfate Metabolites of MK-0966 in Urine of Rats Dosed Orally with MK-0966 (100 mg/kg) [Vol. 1.46; p. G-652]	L-748,731-000R009
	Nov. 12, 1997	G-23: Isolation and Identification of trans-Dihydro-MK-0966 Lactone, a Metabolite of MK-0966, From Unite of Dogs Following Intravenous Administration of [14C]MK-0966 at 2 mg/kg. [Vol. 1.46: p. G-655]	[¹⁴ C]L-748,731-002V008
	Dec. 2, 1997	G-26: Metabolite Profiles of Plasma and Urine From Mice Following Oral Administration of [14C]MK-0966 at 5 mg/kg/ and of Plasma from Rats After Intravenous (2mg/kg/) or Oral (5 mg/kg) Administration of [14C]MK-0966 [Vol. 1.46; p. G-761]	[¹⁴ C]L-748,731-002V002
	Oct. 12, 1997	G-27: In Situ Metabolism of [14C]L-755,190, a Metabolite of MK-0966, in the Rat Isolated Intestinal Segment Model [Vol. 1.46; p. G-773]	[¹⁴ C]L-755,190-001K001
	Nov. 4, 1997	G-28: Identification of L-755,190 as the Major Metabolite of MK-0966 in Incubations with Liver Microsomal Preparations From Phenobarbital-Pretreated Rats [Vol. 1.46; p. G-806]	[¹⁴ C]L-748,731-002∨001
	Feb. 4, 1998	G-29: The Metabolism of MK-0966 by Liver Subcellular Fractions From Human, Monkey, Dog and Rat [Vol. 1.46; p. G-816]	L-748,731-000R009
	Nov. 4, 1997	G-30: Reductive Metabolism of MK-0966 by Human Liver Cytosol [Vol. 1.46; p. G-827]	L-748,731-000R009
	Oct. 10, 1997	G-31: The Cytochrome P-450 Mediated Oxidation of MK- 0966 to L-755,190 by Human Liver Microsomes [Vol. 1.46; p. G-851]	L-748,731-000R009
	Feb. 2, 1998	G-32; Non-Cytochrome P-450-Mediated Oxidation of MK- 0966 to L-755,190 by Hepatic Subcellular Fractions [Vol. 1.46; p. G-870]	L-748,731-000R009
	Nov. 21, 1997	G-33: Kinetics of the In Vitro Metabolism of MK-0966 by Human Liver S9 and Cytosolic Fractions [Vol. 1.46; p. G- 881]	L-748,731-000R009 L-755,190-000H007
	Oct. 13, 1997	G-34: Effects of Cimetidine and Ketoconazole on the In Vitro Metabolism of MK-0966 by Human Liver Microsomes, S9 Fractions and Cytosol [Vol. 1.46; G-901]	L-748,731-000R009

Report No.	Report Date	Study Title	Test Material Lot
	Sept. 22, 1997	G-35: Evaluation of MK-0966 as an Inhibitor of Human Liver Microsomal Cytochrome P-450 Activity [Vol. 1.46; p. G-913]	L-748,731-000R009
TT # 93-283-0, -5 Gene Tox TT #93- 8988	Dec. 10, 1993 Memo	Q-2: Exploratory Enzyme Induction Study in Rats of L-748,731, a COX-2 Inhibitor [Vol. 1.49; p. Q-57]	Not provided
TT #94-253-0, -2 GeneTox TT #94- 8905	Nov. 14, 1994	Q-4: Exploratory Enzyme Induction Study in Rats of L-748,731, a Cox 2 Inhibitor [Vol. 1.49; Q-70]	Not provided
TT #93-283 -0,-5	Jan. 30, 1995 Memo	Q-12: Western and Northern Blots from Exploratory Enzyme Induction Study in Mice [Vol. 1.51; p. Q-1009]	Not provided
TT #93-281-0, -2	Jan. 30, 1995 Memo	Q-14: Western and Northern Blots from Exploratory Enzyme Induction Study in Rats [Vol. 1.51; p. Q-1009]	Not provided
TT #98-049-0	July 17, 1998	Q-6: MK-0966: Sixteen-Day Oral Toxicokinetic Study Dogs [Vol. 1.49; Q-129]	L-748,731-000R069
TT #93-281-0, -2	Nov. 22, 1994 Memo	Q-13: Characterization of P-450 Activities in Microsomal Samples Using Testosterone Hydroxylation Assay	Not provided
DMPK Report No. 97015	April 1, 1997 Memorandum	C-139: CNS Penetration of MK-966 [L-748,731] in the Rat [Vol. 1.3]	L-748,731-000R002
		GENOTOXICITY STUDIES	
In Vitro Studies			<u> 1860 - Johan John M. H. Johnson</u>
TT #94-8024 TT #91-8026	Aug. 12, 1994	D-1: L-748,731: Microbial Mutagenesis Assay [Vol. 1.32; p. D-39]	L-748,731-000R009
TT #94-8209 TT #94-8220 TT #94-8221	Aug. 16, 1994	D-2: L-748,731: In Vitro Alkaline Elution/Rat Hepatocyte Assay [Vol. 1.32; D-103]	L-748,731-000R009
TT #94-8626 TT #94-8627	Aug. 1, 1994	D-5: L-748,731: Assay for Chromosomal Aberrations In Vitro, in Chinese Hamster Ovary Cells [Vol. 1.32; D-257]	L-748,731-000R009
TT #96-9604	May 29, 1996	D-6: L-748,731: Assay for Chromosomal Aberrations In Vitro, in Chinese Hamster Ovary Cells [Vol. 1.32; D-327]	L-748,731-000R009
TT #95-8510 TT #95-8506 TT #95-8501 TT #95-8503	Aug. 9, 1996	D-8: L-748,731: V-79 Mammalian Cell Mutagenesis Assay [Vol. 1.33; p. D-484]	L-748,731-000R009
In Vivo Studies			
TT #94-8222	Sept. 20, 1994	D-3: L-748,731: In Vivo Alkaline Elution/Rat Liver DNA Damage Assay in Male Rats [Vol. 1.32; D-171]	L-748,731-000R009
TT #94-8223	Sept. 16, 1994	D-4: L-748,731: In Vivo Alkaline Elution/Rat Liver DNA Damage Assay in Female Rats [Vol. 1.32; D-214]	L-748,731-000R009
TT #96-8614 TT #96-8624	Dec. 9, 1996	D-7: MK-0966: Assay for Chromosomal Aberrations In Vivo, in Mouse Bone Marrow [Vol. 1.33; D-403]	L-748,731-000R027
	REPR	ODUCTIVE TOXICOLOGY STUDIES	
Rabbit Studies			
TT #94-737-6	Jan. 4, 1995	C-1: L-748731: Oral Range-Finding Study in Non-Pregnant Rabbits [Vol. 1.23; p. C-142]	L-748,731-000R009
TT# 94-737-5	Feb. 24, 1995	C-2: L-748731: Oral Range-Finding Study in Pregnant Rabbits [Vol. 1.23; p. C-183]	L-748,731-000R009
TT #95-704-0	July 18, 1995	C-3: L-748,731: Oral Developmental Toxicity Study in Rabbits [Vol. 1.23; p. C-269]	L-748,731-000R009
Rat Studies			
TT #94-733-5	Feb. 15, 1995	C-5: L-748731: Oral Range-Finding Reproduction Study in Rats [Vol. 1.24; p. C-396]	L-748,731-000R009
TT #94-733-0	April 19, 1995	C-6: L-748,731: Oral Developmental Toxicity Study in Rats [Vol. 1.24; p. C-597 and Vol. 1.25; p. C-806]	L-748,731-000R009
TT #95-705-0	June 30, 1995	C-7: L-748,731: Oral Fertility Study in Female Rats [Vol. 1.25; p. 860]	L-748,731-000R009
TT #92-721-0	Mar 8, 1996	C-8: L-748,731: Oral Fertility Study in Female Rats with a Recovery Period [Vol. 1.25; p. 860]	L-748,731-000R009

Report No.	Report Date	Study Title	Test Material Lot
TT #95-715-0	Oct. 11, 1995	C-9: L-748,731: Oral Ovulation/Fertilization Study in Fernale Rats [Vol. 1. 26; p. C-1214	L-748,731-000R009
TT #95-716-0	Oct. 11, 1995	C-10: L-748,731: Oral Implantation Study in Rats [Vol. 1.26; p. C-1270]	L-748,731-000R009
TT #95-742-0	Dec. 22, 1995	C-11: L-748,731: Oral Estrous Cyclicity/Ovulation/ Fertilization Study in Fernale Rats [Vol. 1.26;p. C-1316]	L-748,731-000R014
TT #95-739-0	May 20, 1996	C-12: L-748,731: Oral Fertility Study in Female Rats with Gestation Days 15 and 21 Laparotomies [Vol. 1.26; p. C- 1379]	L-748,731-000R009
TT #95-730-0	Jan. 22, 1996	C-13: L-748,731 Fostering/Cross-Fostering Study in Rats [Vol. 1.26; p. C-1437 and Vol. 1.27; p. C-1590]	L-748,731-000R009
TT #96-719-0	Oct. 22, 1996	C-14: L-748,731:Oral Length of Gestation and Parturition Study in Fernale Rats [Vol. 1.27; p. C-1682]	MK-0966-000R027
TT #96-718-0	Nov. 5, 1996	C-15: MK-0966: Oral Study in Rats to Assess Effects on Fetal Ductus Arteriosus [Vol. 1.27; p. C-1900]	L-748,731-000R027
TT #95-706-5	Jun 13, 1995	C-16: L-748,731: Oral Range-Finding Late Gestation and Lactation Study in Rats [Vol. 1.28; p. C-1937]	L-748,731-000R014
TT #95-706-0	Oct. 14, 1996	C-17: L-748,731: Oral Late Gestation and Lactation Study in Rats with Postweaning Evaluation [Vol. 1.28; p. C-2084; Vol. 1.29; p. C-2318]	L-748,731-000R009
TT #95-734-0	Jun. 6, 1996	C-20: L-748,731: Oral Fertility Study in Male Rats [Vol. 1.30; p. C-2786]	L-748,731-000R009
	Beath bear Regard	LOCAL TOLERANCE STUDIES	
TT #95-2701	Dec. 27, 1995	H-1: L-748,731: Exploratory Dermal Irritation Study in Rabbits [Vol. 1.47; p. H-12]	L-748,731-000R025
TT #95-4272	Oct. 26, 1995	H-2: Effect of L-748,731 in the Bovine Comeal Opacity and Permeability [BCOP] Assay [Vol. 1.47; p. H-23]	L-748,731-000R025
TT #-95-4273	Dec. 28, 1995	H-3: L-748,731: Exploratory Primary Eye Irritation Study in Rabbits [Vol. 1.47; p. H-52]	L-748,731-000R025
	S	PECIAL TOXICOLOGY STUDIES	
TT #95-2691	March 31, 1996	Q-1: L-748,731: Acute Oral Phototoxicity Study in Mice [Vol. 1, 49; Q-41]	L-748,731-000R009
TT #95-078-0	April 1,1996	Q-5: L-748,706; L-755,190; Ibuprofen: Exploratory 15- Day Cyclooxygenase Inhibition Study in Female Rats [Vol. 1.49; p. Q-76]	L-755,190-000H007
TT #95-056-0	March 6, 1996	Q-7: L-755,190; Five-Week Oral Toxicity Study in Rats [Vol. 1.49; p. Q-167]	L-755,190-000H007
TT #95-070-0	March 4, 1996	Q-8: L-755,190: Fifteen-Day Intravenous Toxicity Study in Rats [Vol. 1:50; p. Q-472]	L-755,190-000H007
TT #95-073-0	March 15, 1996	Q-9: L-755, 190: Sixteen-Day Intravenous Toxicity Study in Dogs [Vol. 1.50; Q-608]	L-755,190-000H007

Studies not reviewed within this submission

Report No.	Report Date	Study Title	
TT # 95-022-1	Nov. 30, 1995	L-748,731: Sixteen-Day Oral Toxicokinetic Study in Female Rats [Vol. 1.16; p. B-2940]	
	Jan. 29, 1998	G-5: A Repeat Study of the Excretion of Radioactivity in the Urine and Feces of Rats Following Oral Administration of [14C]MK-0966 (5mg/kg)[Vol. 1.45; p. G-322]*	
	April 18, 1997	G-24: An Open, Oral, Single-Dose, 4-Period Study in Healthy Subjects to Investigate t Absorption, Metabolism, Excretion and Mass Balance of [14C]MK-0966 in Solution (Protocol 0120 [Vol. 1.46; p. G-679]	
	Nov. 5, 1997	G-25: Isolation and Identification of Metabolites in Urine of a Human Subject Following Oral Administration of MK-0966 at 250 mg [Vol. 1.46; p. G-750]	
	May 14, 1998	F-30: Ancillary Pharmacology: Effects of Celecoxib, a Cyclooxygenase II[CC Inhibitor, on Renal Function and Electrolyte Excretion in Conscious Dogs [Vol. 1.4 518] ^b	
TT #94-045-0	Feb. 8, 1995	B-20: L-748,706: Fourteen-Week Oral Toxicity Study in Dogs [Vol. 1.21; B-4645]	

Report No.	Report Date	Study Title	
TT #95-069-0	Feb. 26, 1996	B-12: L-748,731: Exploratory Fifteen-Day Cyclooxygenase Inhibition Study in Female Rats. [Vol. 1.17; B-3066]	
TT #95-735-5	April 1, 1996	C-22: Aspirin and Indomethacin: Exploratory Oral Study in Rats to Assess Effects on Fetal Ductus Arteriosus [Vol. 1.30; p. C-2857]	
TT #97-082-0	Dec. 23, 1997	Q-10: L-791,398: Exploratory Single-Dose Oral Toxicokinetic Study in Dogs [Vol. Q-828]	
TT #97-098-0	Dec. 19, 1997	Q-11: L-791,398: Exploratory 16-Day Oral Toxicity Study in Rats [Vol. 1.51; Q-863]	
TT #94-253-0, -2	Jan. 30, 1995	Q-15: Western Blots from Exploratory Enzyme Induction Study in Rats of L-748,731	

*Results of this study are discussed in review of study entitled "Absorption, Distribution, Metabolism, and Excretion of L-748,731 in Rats and Dogs"

^bSponsor's conclusion – Oral celecoxib at 10 mg/kg decreased urine output and Na excretion in 4/5 conscious female dogs, but did not significantly alter GFR, effective renal plasma flow, or filtration fraction.

^cResults of this study are discussed in conjunction with review of Study TT #93-281-0,-2; Western and Northern Blots from Exploratory Enzyme Induction Study in Rats.

<u>Disclaimer (Use of sponsor's material):</u> Sponsor submitted information was utilized in the preparation of this review.

Introduction/Drug History: Cyclooxygenase [COX] or prostaglandin H_2 synthase catalyzes the conversion of arachidonic acid to prostaglandin H_2 [PGH₂]. Subsequently, PGH2 serves as the substrate for a number of enzymes involved in the generation of eicosanoids [e.g. PGE₂, PGD₂, PGF_{2 α}, PGI2, and thromboxane A_2]. The determinant for which end product is formed is, in part, dependent on the specific enzymes present within a given cell type. The eicosanoids play a regulatory role in a number of physiological and pathophysiological processes including renal function, immune function, inflammation, pain, female reproduction, blood vessel tone, and integrative function in the brain.

Two isoforms of the COX enzyme have been identified. Overall, the two isoforms demonstrate a number of structural and biochemical similarities. However, there are several dissimilarities that help explain the apparent functional differences. COX-1 and COX-2 are products of separate genes with 63% sequence homology. COX-2 is able to utilize a larger number of fatty acid substrates than COX-1. However, one of the major differences between these isoforms is in their regulation and expression. COX-1 is constitutively expressed in most normal tissues and appears to be involved in regulation of homeostatic or "housekeeping" functions. COX-2, however, is primarily an inducible enzyme with constitutive expression in a limited number of tissues including the brain, pancreas, and kidney. COX-2 expression is upregulated in response to a number of bioactive endogenous and exogenous molecules such as cytokines [e.g. interleukin-1 and tumor necrosis factoral and lipopolysaccharide. The role of COX-2 in both physiological and disease states has not been fully delineated. However, it is generally accepted that COX-2 activity is associated with the inflammatory response and neutrotransmission involved in the pain response.

The "COX-2 hypothesis" suggests that inhibition of the activity of this isoform will reduce inflammation and ameliorate pain secondary to a number of processes without the adverse effects [e.g. gastrointestinal ulceration, renal toxicity] of non-specific COX inhibition. This is the basis for the development of rofecoxib, a selective COX-2 inhibitor, for the treatment of inflammation associated with osteoarthritis and acute pain.

1. Pharmacology:

The following studies were submitted in a report entitled "Pharmacological studies of L-748,731" [Vol. 1.42; p. F-227] and were compiled at the Merck Frost Centre for Therapeutic Research in Quebec, Canada. The initial Pharmacology/Toxicology Reviewer, Dr. Will Coulter, reviewed the majority of these studies. Additional comments by the current Pharmacology/Toxicology are in italics.

1.1 PHARMACOLOGICAL STUDIES OF L-748,731 - In Vitro Studies

1.1.1 *IN VITRO* STUDIES OF L-748,731

1) Effects of L-748.731 in Whole Cell Cyclooxygenase Assays [Vol. 1.42; p. F-241]:

The results of the effects of indomethacin and L-748,731 on PGE₂ synthesis by human histiocytic lymphoma U-937 cells (express only COX-1) and by human osteosarcoma 143 cells (express only COX-2) in response to 10 µM arachidonic acid are indicated in the following table [p. F-245].

		IC ₅₀ (nM)	
	U-937 Cells	Osteosarcom	a Cells
	(COX-1)	(COX-2	
Indomethacin	10 (n=3)*	20 (n=	
Regional grand find			
L-748,731	>50,000 (n=4	26 ± 10 (1)	n=5)
		<10 (n=	

^{*} Tests were done in triplicate at 3-6 concentrations, with n equal to the number of times the compound was tested.

In this assay, L-748,731 was approximately 1000X more potent as an inhibitor of COX-2 compared to COX-1.

2) Effects of L-748,731 in Human and Dog Kidney Microsomal Cyclooxygenase Assays [Vol. 1.42; p. F-246]

The effects of indomethacin and L-748,731 on PGE₂ synthesis by human, dog, and rat kidney microsomal preparations in response to arachidonate are shown below [p. F-249].

IC ₅₀ (μM)
Human Dog Rat
Indomethacin $0.30 (n=8)^* 0.25 (n=2) 0.32 (n=3)$
L-748,731 14 (n=4) > 30 (n=2) > 30 (n=3)

^{*} Tests were done in duplicate at 4-9 concentrations, with n equal the number of times the drugs were tested.

 IC_{50} values were higher in rats and dogs than in humans. A maximum inhibition of approximately 70-90% was observed in the human microsomal preparations. However, it appears from the information presented that there was minimal to no inhibition seen in dog or rats at the highest concentrations used.

3) Effects of L-748,731 on Cyclooxygenase Activity of U-937 Cell Microsomes [Vol. 1.42; p. F-249] When the cyclooxygenase assay was carried out with U-937 cell microsomes, which express COX-1 selectively, and 0.1 μM arachidonic acid, L-748,731 inhibited the production of PGE₂ (IC₅₀ ≈ 7 μM), but was less potent than indomethacin (IC₅₀ ≈ 30 nM). These results are in fair agreement with the results above in 1 using 10 μM arachidonic acid.

4) Studies of Kinetic Mechanism of COX Inhibition by L-748,731 [Vol. 1.42; p. F-251]

The results of kinetic mechanism studies of L-748,731 on the purified and microsomal recombinant hCOX-1 and hCOX-2 indicated a two step mechanism ["a rapidly reversible binding of enzyme followed by a slow isomerization to a tightly bound inhibited complex [which is]...only very slowly reversible"] was involved in microsomal hCOX-2 inhibition, with a $K_i = 6$ nM. On the other hand, a weak and rapidly reversible inhibition of hCOX-1 ($IC_{50} \approx 15 \mu M$) was determined.

5) Effect of L-748,731 or Indomethacin on Human Platelet Aggregation [Vol. 1.42: p. F-268]:

No effect was seen at 10 μ M on the rate of collagen, ADP, or U-46619 (a thromboxane mimetic) induced aggregation of human gel-filtered platelets. The nonspecific cyclooxygenase inhibitor, indomethacin, at 10 μ M inhibited the rate of platelet aggregation by 28% in the presence of collagen activation, but not in the presence of ADP or U-46619. Collagen induced aggregation was said to proceed by a cyclooxygenase dependent pathway. The level of inhibition with indomethacin was low. It would have provided additional insight if a dose response for both compounds had been conducted.

6) Effect of L-748,731 in Lipopolysaccharide (LPS)-Induced Human Whole Blood PGE₂ and Serum TXB₂ Assays [Vol. 1.42; p. F-270]

Since normal human blood does not contain COX-2, L-748,731 would not show an effect on PGE₂ production. However, COX-2 was induced after incubation with LPS. A concentration dependent inhibition of PGE₂ synthesis was then seen in human whole blood with L-748,731 (IC₅₀ = 0.59 μ M) or with indomethacin (IC₅₀ = 0.50 μ M).

Platelets contain large amounts of COX-1 and are activated during blood clotting. During this clotting, thromboxane A_2 (TXA₂) is generated. This was assayed by measuring its stable metabolite, TXB₂. Both indomethacin (IC₅₀ = 0.16 μ M) and L-748,731 (IC₅₀ = 13.12 μ M) produced a concentration dependent inhibition of TXB₂ with a maximum inhibition of 90% and 64%, respectively.

In this assay, L-748,731 is approximately 20X more selective as an inhibitor of COX-2 compared to COX-1.

7) Effect of L-748,731 on LPS Induced PGE₂ Generation by Human and Rat Mononuclear Cells [Vol. 1.42; p. F-275];

There was no significant difference between the inhibition of LPS induced PGE₂ synthesis with L-748,731 (IC₅₀ = 29 μ M) or indomethacin (IC₅₀ = 26 μ M) in human mononuclear cells. In rat mononuclear cells the IC₅₀ values were 23 nM (L-748,731) and 87 nM (indomethacin).

8) Effects of L-748.731 on Arachidonic Acid (AA) Induced PGE₂ Production in LPS Stimulated Dog Blood [Vol. 1.42; p. F-280]

L-748,731 produced a dose related inhibition of PGE₂ (AA induced) in LPS stimulated dog whole blood. At 62 μ M a 62% inhibition was seen (IC₅₀ = 10.8 μ M). Diclofenac also produced a dose related inhibition which was >90% at 3 μ M (IC₅₀ = 0.14 μ M)

1.1.2 MISCELLANEOUS SPECIFICITY STUDIES:

1) Effect of L-748.731 on LTB, Biosynthesis by Isolated PMNs [Vol. 1.42; p. F-283];

This system is a "cell-based assay" used for assessment of leukotriene biosynthesis. L-748,731 (0.31 to 25 μ M) was said to have no significant effect [0-30%] on the inhibition of LTB₄ derived from polymorphonuclear leukocytes (PMN) that were challenged with A23187. A23187 is a divalent calcium ionophore that stimulates PMN production of LTB₄.

2) Studies of L-748.731 on 15-Lipoxygenase Activity [Vol. 1.42; p. F-285]

Minor inhibition [0 and 18% in 2 experiments] was said to be produced by 20 μ M L-748,731 [0.7 -20 μ M] on 15-lipoxygenase derived from human leukocytes. The positive control resulted in 90% inhibition at 20 μ M. This enzyme oxidizes arachidonic acid to 15-HETE. The IC₅₀ was >20 μ M.

3) Effect of L-748,731 on TXB₂ and 12-HETE Production by Calcium Ionophore Activated Human Platelets [Vol 1.42; p. F-286]

These synthetic pathways involve the activity of 12-lipooxyegenase or COX-1 and thromboxane synthase. No significant reduction (<15%) of the release of TXB₂ and 12-HETE occurred when human platelets were activated by the calcium ionophore A23187 in the presence of L-748,731[1, 5, and 20 μ M]. The IC₅₀ was >20 μ M.


4) Studies of L-748,731 on LTD₄, LTB₄, and CB₂ Receptors [Vol. 1.42; p. F-288]
L-748,731 was inactive as a competing ligand at the LTD₄, LTB₄, and CB₂ receptors.

1.1.3 IDENTIFICATION OF COX-1 [PGHS] IN GASTROINTESTINAL TRACT

1) Expression of COX-1 in the GI Tract of Rat. Dog. Squirrel Monkey, and Human [Vol. 1.42: F-311]:

This study quantitated the levels of prostaglandin G/H synthase-1 (PGHS-1) in several species, including humans. The results are shown in the following figure (p. F-314).

Expression of PGHS-1 in the GI tract (ng/mg microsomal protein)



There was considerable variability in the pattern of COX-1 distribution in the various species evaluated. The rank order of COX-1 levels throughout the GI tract was generally humans>monkey>dog>rat. The COX-1 levels in the stomachs of the squirrel monkey, however, were greater than that observed in humans. The Sponsor suggests that there "appear[s] to be an inverse relationship between levels of PGHS-1 protein observed and the sites within the gastrointestinal tract where ulceration is commonly observed".

1.1.4 Receptor Binding Specificity

1) Specificity of Action (Panlabs) of L-748,731 [Vol. 1.42; p. F-351]

L-748,731 was submitted to to evaluate for any undetected receptor binding [up to $10 \mu M$] and enzyme assays [up to $300 \mu M$] in their Significant activity was not seen in the binding of 28 radiolabeled ligands to their respective receptors or in the inhibitory activity of 5-lipoxygenase, 15-lipoxygenase, lipid peroxidase, phospholipase A_2 , and protein kinase C, calpain, and EGF tyrosine kinase enzymes.

The following studies were submitted in a report entitled "Additional In Vitro Biochemical Studies of MK-0966" [Vol. 1.42; p. F-356]] and were conducted at the Merck Frosst Centre for Therapeutic Research in Quebec, Canada. The current Pharmacology/Toxicology Reviewer reviewed the following studies. A signed QA statement was provided.